Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 101
Filter
1.
Dermatologica Sinica ; 40(2):67-70, 2022.
Article in English | EMBASE | ID: covidwho-1957509

ABSTRACT

With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns about the safety of systemic treatments of immune-mediated dermatologic disorders has been raised by dermatologists and their patients. We aimed to perform a rapid review of latest American and European guidelines on the use of systemic treatments in patients with immune-mediated dermatologic disorders and confirmed COVID-19 infection and to provide recommendations to inform practice. Based on the current limited guidelines and evidence, systemic corticosteroids should not be abruptly discontinued and the lowest effective dose should be continued. Systemic immunosuppressants (including methotrexate, cyclosporine, azathioprine, cyclophosphamide, and leflunomide), biologics, and sulfasalazine should be withheld in patients with confirmed COVID-19 infection. Whether to continue Janus kinase inhibitors should be determined following a shared decision-making process between dermatologists and patients after considering patients' medical conditions and risk for severe COVID.

2.
European Journal of Clinical Pharmacy ; 23(4):244-248, 2021.
Article in English | EMBASE | ID: covidwho-1955738

ABSTRACT

Background:As the pandemic progresses, we are growing increasingly aware that COVID-19 affects multiple parts of the body beyond the lungs. Objective: We aimed to review the literature to outline the COVID-19 effect on hair, vision, thinking, hearing, fertility, taste and smell, skin and gastro-intestine (GI), and its health crisis among COVID-19 infected patients.Method: We searched the database «PubMed» which included studies that measured COVID-19 effect on hair, vision, thinking, hearing, fertility, taste and smell, skin, and GI. Results: A total of 60 studies were reviewed and screened based on titles and s. Of these, only 15 studies were determined to meet the eligibility criteria for discussion. The health crisis associated with hair, vision, thinking, hearing, fertility, taste and smell, skin, and GI were baldness, hair shedding, conjunctivitis, pink-eye syndrome, sore-eyes, brain fog, short-term memory loss, reduction in male sperm concentration, altered sperm cell shape, morbidity, tinnitus, loss of hearing, reduce taste and loss of smell, acne, eczema, psoriasis, and rosacea, lacy and dusky rashes on the skin, loss of appetite, nausea, vomiting diarrhea, and abdomen pain. Conclusion: Scientists, researchers and clinicians are still learning, observing and knowledge is evolving daily related to COVID-19 infection.

3.
J Clin Med ; 11(15)2022 Jul 22.
Article in English | MEDLINE | ID: covidwho-1957360

ABSTRACT

The implementation of precautionary measures, such as wearing a mask and social distancing, may have affected allergic diseases during the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to compare the numbers of medical visits for allergic diseases before and during the COVID-19 pandemic. Data were obtained from the Korean National Health Insurance claims database. Monthly numbers of patients for four allergic diseases, i.e., allergic rhinitis (AR), asthma, atopic dermatitis (AD), and allergic conjunctivitis (AC), were evaluated using ICD-10 codes and compared between the 'before COVID-19' period from January 2018 to February 2020, and the 'during COVID-19' period from March 2020 to June 2021, since the first COVID-19 patient was detected on 20 January 2020, in Korea. Subgroup analyses were performed according to age and sex. The mean numbers of medical visits for AR and asthma were significantly greater before COVID-19 than those during COVID-19 (both p < 0.001). The variance in the number of medical visits for asthma decreased during the COVID-19 pandemic. However, the mean number of medical visits for AD increased slightly during COVID-19 and that for AC did not change before and during the COVID-19 pandemic. In subgroup analyses, the results showed a similar pattern to that of the total number of participants, regardless of age and sex. In conclusion, medical visits for AR and asthma significantly decreased during the COVID-19 pandemic, regardless of age and sex.

4.
Pharmacol Res ; 183: 106362, 2022 Jul 22.
Article in English | MEDLINE | ID: covidwho-1956292

ABSTRACT

The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of the adjacent protein kinase domain (JH1). The Janus kinase family is regulated by numerous cytokines including interferons, interleukins, and hormones such as erythropoietin and thrombopoietin. Ligand binding to cytokine receptors leads to the activation of associated Janus kinases, which then catalyze the phosphorylation of the receptors. The SH2 domain of signal transducers and activators of transcription (STAT) binds to the cytokine receptor phosphotyrosines thereby promoting STAT phosphorylation and activation by the Janus kinases. STAT dimers are then translocated into the nucleus where they participate in the regulation and expression of dozens of proteins. JAK1/3 signaling participates in the pathogenesis of inflammatory disorders while JAK1/2 signaling contributes to the development of myeloproliferative neoplasms as well as several malignancies including leukemias and lymphomas. An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and about 50% of cases of myelofibrosis and essential thrombocythemia. Abrocitinib, ruxolitinib, and upadacitinib are JAK inhibitors that are FDA-approved for the treatment of atopic dermatitis. Baricitinib is used for the treatment of rheumatoid arthritis and covid 19. Tofacitinib and upadacitinib are JAK antagonists that are used for the treatment of rheumatoid arthritis and ulcerative colitis. Additionally, ruxolitinib is approved for the treatment of polycythemia vera while fedratinib, pacritinib, and ruxolitinib are approved for the treatment of myelofibrosis.

5.
Biomedicines ; 10(5)2022 May 20.
Article in English | MEDLINE | ID: covidwho-1952993

ABSTRACT

BACKGROUND: Interleukin-33 (IL-33) is an important cytokine in the pathophysiology of atopic dermatitis (AD) and in the progression of COVID-19. Angiotensin converting enzyme 2 (ACE2), the entry receptor for SARS-CoV-2, is expressed in epidermal keratinocytes. Whether IL-33 could regulate the expression of ACE2 mechanistically in keratinocytes warrants investigation. OBJECTIVE: We questioned whether the ACE2 expression is increased in AD skin. We also questioned whether ACE2 is expressed in keratinocytes; if so, would its expression be enhanced mechanistically by IL-33. METHODS: We measured and compared the expression of ACE2 in skin from patients with AD, patients with psoriasis, and healthy controls using immunohistochemistry. Flow cytometry, immunofluorescent exam, and quantitative RT-PCR were used for measuring the ACE2 expression in cultured keratinocytes treated with IL-33 and IL-17. Blocking antibodies were utilized to study the intracellular signaling pathways governing the ACE2 expression using cytokines. RESULTS: The results showed that the ACE2 expression is increased in AD compared with that in healthy skin and psoriasis. In primary epidermal keratinocytes, ACE2 is constitutively expressed. IL-33 induces a time-dependent increase in ACE2 expression in cultured keratinocytes through quantitative PCR, flow cytometry, and immunofluorescent examinations. Furthermore, pretreatment of an ERK inhibitor, but not a STAT3 inhibitor, eliminated the increases in ACE2 by IL-33 in keratinocytes, indicating that IL-33 enhances ACE2 expression through ERK on epidermal keratinocytes. CONCLUSION: This is the first study to reveal that IL-33 enhances ACE2 expression on keratinocytes via ERK. Although further mechanistic studies are required, the increased ACE2 expression in IL-33 might have a biological implication on the transmission of SARS-CoV-2 in patients with AD.

6.
Dermatitis ; 33(3):e38, 2022.
Article in English | EMBASE | ID: covidwho-1937764

ABSTRACT

Objectives: The COVID-19 pandemic might disproportionately impact patients with atopic dermatitis (AD). We aimed to investigate associations between COVID-19- related impact and AD severity among adults in the Dutch general population. Methods: This cross-sectional study was conducted within the Lifelines Cohort Study. A digital questionnaire was sent out to 135,950 adult participants to collect data on AD in 2020. COVID-19-related variables were collected by regularly sending out questionnaires to 139,735 adult participants betweenMarch 2020 and July 2021. Associations between AD severity and COVID-19-related impact were analyzed using binary logistic regression models. Results: In total, 53,545 subjects, who responded to the AD questionnaire and at least one COVID-19 questionnaire, were included. Multivariate analysis showed similar COVID-19 infection rates in all groups. Subjects with AD, regardless of disease severity, were more concerned about the COVID-19 crisis and more often chose to not contact a doctor when having health problems. Subjects with mild AD had a higher COVID-19 vaccination rate and more frequently covered mouth and nose in public. Moreover, subjects with moderate-to-severe ADestimated a higher chance of becoming infected and expected a more serious disease course. They were more worried about getting sick and a medication shortage, and tended to take other precautions. They also more often expected, reported, and were more afraid of COVID-19 vaccines side effects. Conclusions: The COVID-19 pandemic has a considerable impact on patients with moderate-to-severe AD, highlighting the need of more attention for their overall wellbeing in daily practice during the current pandemic.

7.
Contact Dermatitis ; 86(SUPPL 1):45, 2022.
Article in English | EMBASE | ID: covidwho-1927573

ABSTRACT

Background: Atopic dermatitis (AD) causes a considerable public health burden, especially among patients with moderate-to-severe disease. A large epidemiological study has not been conducted in the Netherlands. Objectives: To investigate the prevalence and severity of AD in the Dutch general population and its associations with lifestyle factors and COVID-19-related impact. Methods: A cross-sectional study was conducted within the Lifelines Cohort Study by sending an AD questionnaire in 2020 and multiple COVID-19 questionnaires between 2020 and 2021, to 139 735 adults. Lifestyle factors were collected at baseline between 2006 and 2013. Associations between AD, lifestyle factors, and COVID-19-related impact, were analysed using binary logistic regression and/or linear regression models. Results: 57643 subjects (42.5%) responded to the AD questionnaire, of those 53 545 responded to at least one COVID-19 questionnaire. The lifetime prevalence was 9.3%, and the point prevalence of moderate-to-severe AD was 2.3%. Moderate-to-severe AD was associated with smoking pack-years, >2 alcoholic drinks per day, chronic stress, and obesity. Moreover, the COVID-19 pandemic had a greater psychological impact on the subjects with moderate-to-severe AD, who were also more concerned about COVID-19 vaccines and healthcare system and tended to take more precautions for prevention. Conclusions: Moderate-to-severe AD represents a large proportion of AD patients and shows positive associations with lifestyle factors and a profound COVID-19-related impact. More attention to lifestyle factors and patient's overall welling appears warranted in those severely affected. Further longitudinal studies are required to better characterize the direction of these associations and develop strategies for coping.

8.
Allergol Int ; 71(3): 310-317, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1926162

ABSTRACT

In October 2021, researchers from the German Society of Allergy and Clinical Immunology (DGAKI) and from the Japanese Society of Allergology (JSA) focused their attention on the pathological conditions and modifiers of various allergic diseases. Topics included 1) the pathophysiology of IgE/mast cell-mediated allergic diseases; 2) the diagnosis and prevention of IgE/mast cell-mediated diseases; 3) the pathophysiology, diagnosis, and treatment of eosinophilic airway diseases; and 4) host-pathogen interaction and allergic diseases. This report summarizes the panel discussions, which highlighted the importance of recognizing the diversity of genetics, immunological mechanisms, and modifying factors underlying allergic diseases.


Subject(s)
Hypersensitivity , Immunoglobulin E , Humans , Hypersensitivity/drug therapy , Hypersensitivity/therapy
9.
Journal of Applied Research on Children ; 12(1), 2021.
Article in English | ProQuest Central | ID: covidwho-1918891

ABSTRACT

As a teenager with severe atopic dermatitis and asthma living in Puerto Rico, life has presented me with many obstacles and challenges that have shaped me into who I am. Living through powerful hurricanes, earthquakes and the COVID-19 pandemic has shone a bright light on the immediacy of the climate crisis. Our future is at stake, and the countdown to prevent and prepare is running out. I am discovering my role in promoting climate action as a vested stakeholder. How can an adolescent help and truly make a difference in the mitigation of climate change? Analyzing these issues from the intimate perspective of intergenerational environmental justice and an ever-growing passion for the environment, stirs the pot (PFOA free) to activate the environmental conscience in every reader. Key Take Away Points As a teenager with severe atopic dermatitis and asthma living in Puerto Rico, life has presented me with many obstacles and challenges that have shaped me into who I am. Living through powerful hurricanes, earthquakes and the COVID-19 pandemic has shone a bright light on the immediacy of the climate crisis. Our future is at stake, and the countdown to prevent and prepare is running out. I am discovering my role in promoting climate action as a vested stakeholder. How can an adolescent help and truly make a difference in the mitigation of climate change? Analyzing these issues from the intimate perspective of intergenerational environmental justice and an ever-growing passion for the environment, stirs the pot (PFOA free) to activate the environmental conscience in every reader.

10.
Acta Dermato-Venereologica ; 102(SUPPL 222):26, 2022.
Article in English | EMBASE | ID: covidwho-1917142

ABSTRACT

Adverse skin reactions are frequently reported by healthcare workers (HCWs) using face personal protective equipment (F-PPE) during the COVID-19 pandemic (Skiveren 2022). The skin is constantly provoked due to occlusion and friction by using F-PPE. This leads to itchy, dry, irritated, scaly and or red skin, which can be associated with eczema. This study is based on self-reported symptoms. Purpose: To describe the prevalence of red and irritated skin and risk factors related to the use of F-PPE among frontline HCWs at six Danish hospitals. Methods: A questionnaire survey was sent electronically to 22.993 HCWs. Results: The response rate was 44.7% (n=10.287). Of those, who used both surgical masks and FFP2-3, 37.8% (n=3893) reported red and irritated skin. Nurses were the largest group of responders (n=5924, 71.8%) and had significant more often red and irritated skin (n=2530, 42.7%) than physicians (n=553, 23.7%). Female HCWs (n=8854, 86.1%) had significant (p>0.001) more often symptoms (n=3575, 40.4%) than men (n=318, 22.2%). The responders who reported chronic skin disease like atopic dermatitis (n=560) had more often red and irritated skin (53.2%) than those without (37.0%) (p<0.001). Some skin types were more prone to have red and irritated skin;sensitive skin (42.2% based on n=1998), combined skin (42.2% based on n=1453), dry skin (32.2% based on n=5263), and oily skin (31.4% based on n=986). The difference between the skin types was significant, unless between dry and oily skin (p=0.629). Conclusions: To minimize adverse skin reactions due to the use of F-PPE, individual risk assessment is needed.

11.
Pediatric Dermatology ; 39(SUPPL 1):12, 2022.
Article in English | EMBASE | ID: covidwho-1916267

ABSTRACT

Objectives: Atopic dermatitis is a common pediatric cutaneous inflammatory disease. Moderate and severe cases are associated with a signed parental burden. Therapeutic parental education, regular follow-up, written treatment plans, and spending enough time with the patient have positively impacted burden reduction. In order to maintain social distancing during the COVID-19 pandemic, direct dermatological consultations were reduced. The survey focused on the mode of consultations done for Atopic Dermatitis during the pandemic and the satisfaction regarding the same, self-reported details regarding flares of the disease - frequency and duration, and parental-care giver burden during this socialdistancing demanding period. Method: An electronic survey was distributed among parents of children aged from 0 to 16 years with atopic dermatitis in Saudi Arabia between October 12 and December 12, 2020. The survey discusses the different burdens during and before the pandemic, including financial, number and period of flares, sleep quality, job quality, and the treatments used. The study also discusses the type of earned medical advice, including onsite visits, virtual consultation, others or none. Results: A total of 242 caregivers responded;103 female and 139 male children. Of these, 145 respondents had consultations during the pandemic, including 72 (49.7) onsite consultations. Out of the 73 (50.3%) online respondents, 53.4% were satisfied, than 35.6% were unsatisfied with the consultation, while the rest had a neutral opinion. Moreover, the parental burden before and during the pandemic seems similar. Discussion: Teledermatology represents an effective method in treating pediatric atopic dermatitis and avoiding the deterioration of the related parental quality of life in case of physically unreachable medical services.

12.
Pediatric Dermatology ; 39(SUPPL 1), 2022.
Article in English | EMBASE | ID: covidwho-1912840

ABSTRACT

The proceedings contain 169 papers. The topics discussed include: GNAQ/11 mosaicism causes aberrant calcium signaling and drives systemic hypocalcemia;pediatric obesity and skin disease (PicoSkin-study): cutaneous findings and associated quality of life in 86 children and adolescents with obesity;what gives them the shivers? two new cases of infantile transient smooth muscle contraction of the skin;dermatologic manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic;clinical characteristics and management of cutaneous lymphangioma circumscriptum;different shades of grey! infantile black hairy tongue- a case series and review of the literature;descriptive series of cases of pediatric linear morphea in a tertiary hospital in Barcelona;the prevalence of itch in German schoolchildren: a population-based study;neurocognitive functioning, physical health, and mental health of school-aged children treated with propranolol or atenolol for infantile hemangioma;and efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.

13.
J Am Acad Dermatol ; 2022 Jun 25.
Article in English | MEDLINE | ID: covidwho-1907219
14.
Australasian Journal of Dermatology ; 63(SUPPL 1):21-22, 2022.
Article in English | EMBASE | ID: covidwho-1883170

ABSTRACT

Aim: Occupational contact dermatitis (OCD) is common amongst healthcare workers (HCW). This retrospective study describes the causes of allergic contact dermatitis in HCW in New Zealand and reviews the current literature review on OCD in HCW during the COVID-19 pandemic. Material and Methods: All HCW undergoing patch testing between July 2008 and January 2020 at a public hospital patch-test clinic, and between June 2019 and January 2020 at a private dermatology clinic were included. Data collected included patient demographics, occupation, results of patch testing and pre and post-patch test diagnoses. Literature search was performed on Pubmed with keywords: healthcare workers, occupational, allergic contact dermatitis (ACD), irritant contact dermatitis (ICD), COVID-19. Results: Out of 837 patients patch tested during the study period, 67 were HCW. The mean age of HCW was 41 years (standard deviation 14) and 58 (87%) were female. The most common occupations were nurses (40%), allied health (22%) and doctors (18%). Forty-six (69%) patients had a background of atopic dermatitis. Hand dermatitis was the most common presentation (49%), followed by facial/neck dermatitis (25%). The most common relevant positive reactions were to rubber accelerators (24%), fragrances (16%), perservatives (15%) and topical steroids (9%). Literature review reflects that the incidence of ICD increased significantly due to increased frequency of hand washing and use of personal protective equipment during the COVID-19 pandemic. Contemporary data regarding ACD is limited. Conclusion: The most common allergens in HCW are rubber chemicals, fragrances and preservatives. The COVID- 19 pandemic has highlighted the incidence of OCD amongst HCWs. While rates of ICD have risen, data does not yet suggest increased rates of ACD.

15.
8th IEEE International Conference on Problems of Infocommunications, Science and Technology, PIC S and T 2021 ; : 80-84, 2021.
Article in English | Scopus | ID: covidwho-1878968

ABSTRACT

Currently, the relevance of remote express diagnostics of various diseases is beyond doubt. The active spread of various types of epidemics and pandemics necessitates the improvement of various types of express diagnostics. The authors conduct research in the field of remote visual diagnostics using modern methods of processing telemedicine video information. This paper discusses the possibility of improving the quality of visualization of diagnostic signs using the digital dermatoscopy method for express diagnostics of skin rashes in COVID-19 in comparison with the manifestations of atopic dermatitis. The prospect of this work is the study of illumination conditions during registration and selection of skin areas for the analysis of diagnostic images. © 2021 IEEE.

16.
Int J Womens Dermatol ; 8(1): e002, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1874037

ABSTRACT

Pregnant women with allergies face difficulties, as they tend to avoid medication for symptom control during pregnancy. Moreover, some women experience exacerbations during this period. These difficulties can affect their mental health. Objective: This study aimed to investigate the factors influencing allergy exacerbations during pregnancy and examine the effects of allergy symptoms on the mental health of pregnant women. Methods: A cross-sectional study was conducted through web-based research in March 2020, amid the COVID-19 pandemic. Pregnant women were collected from 3 groups (target: 150 participants in each group): atopic dermatitis (AD), allergic rhinitis, and without allergies. We evaluated mental health using Kessler Psychological Distress Scale (K6) and health-related quality of life using the Short Form-8 questionnaire. Results: Overall, 202 (49.1%) of 411 pregnant women had depressive symptoms, and 45 (10.9%) had severe depressive symptoms. Women with allergies had significantly worse mental health than those without allergies. Among 119 AD patients, 36 (30.3%) experienced exacerbations during pregnancy. Of them, 11 (30.6%) did not consult a practitioner and endured the exacerbation. A significant association was observed between severe prepregnancy symptoms, job situation, coping with symptoms of AD during pregnancy, and AD exacerbation. Among 210 rhinitis patients, 17.1% experienced rhinitis exacerbation during pregnancy. The presence of rhinitis symptoms in winter and the second trimester was significantly associated with exacerbation. Conclusion: This study revealed higher rates of depressive symptoms among pregnant women with allergies. The psychological well-being of pregnant women with AD or allergic rhinitis should be considered.

17.
Journal of Clinical and Aesthetic Dermatology ; 15(4 SUPPL 1):S13, 2022.
Article in English | EMBASE | ID: covidwho-1866155

ABSTRACT

Background: ASLAN004 is a fully human monoclonal antibody that binds to IL-13Ra1 with high affinity and inhibits IL-4 and IL-13 signaling via the Type 2 cytokine receptor, an important target in atopic dermatitis (AD). Objective: To evaluate the emerging safety, tolerability, and efficacy of ASLAN004 in a multipleascending dose escalation phase in patients with moderate to severe AD. Methods: Twenty-five adult patients with moderate to severe AD were recruited from the US, Australia and Singapore and randomized 3:1 in three cohorts to receive once weekly 200, 400 or 600mg of subcutaneous ASLAN004 or matching placebo over eight weeks, with a 12-week recovery period. An interim data readout was conducted after Cohorts 1-3 completed eight weeks of treatment to evaluate various clinical endpoints in a limited number of patients before conducting an expansion cohort (Cohort 4, results reported elsewhere). Endpoints in the interim analysis include change from baseline in Eczema Area Severity Index (EASI) score at week 8 and safety assessments including local tolerability and incidence of adverse events (AEs). [NCT04090229] Results: Three of 25 patients randomized into Cohorts 1-3 discontinued due to restrictions imposed in response to the COVID-19 pandemic. 18 of the remaining 22 patients in the planned interim data readout completed at least 29 days of dosing and assessment and were evaluable for efficacy. The mean ± SD (n=18) baseline scores were 32.5±11.8 for EASI and 44% had severe Investigator Global Assessment (IGA) scores. At Week 8, mean reductions in EASI from baseline were 50 percent, 74 percent and 76 percent for the 200mg (n=4), 400 mg (n=6) and 600 mg (n=3) ASLAN004 dose groups respectively, compared with 42 percent (n=5) for placebo. Mean reductions of peak pruritus from baseline to Week 8 were 34 percent, 48 percent and 39 percent for 200mg (n=4), 400mg (n=6) and 600mg (n=2) ASLAN004 dose groups respectively, compared with 16% for placebo (n=5). Other secondary endpoints were also improved for ASLAN004 compared with placebo (EASI-50, EASI- 75, results reported elsewhere). The proportion of patients with AEs and treatment-emergent adverse events (TEAEs) were similar across ASLAN004 treatment and placebo arms. There were no TEAEs leading to discontinuation in the ASLAN004 treatment groups. Conclusion: ASLAN004 was well tolerated, with 400mg and 600mg showing promising eicacy in adults with moderate to severe AD.

18.
Stem Cell Res Ther ; 12(1): 539, 2021 10 11.
Article in English | MEDLINE | ID: covidwho-1854868

ABSTRACT

Allergic diseases are immune-mediated diseases. Allergies share a common immunopathogenesis, with specific differences according to the specific disease. Mesenchymal stem/stromal cells (MSCs) have been applied to people suffering from allergic and many other diseases. In this review, the immunologic roles of MSCs are systemically reviewed according to disease immunopathogenesis from a clinical viewpoint. MSCs seem to be a promising therapeutic modality not only as symptomatic treatments but also as causative and even preventive treatments for allergic diseases, including atopic dermatitis and chronic urticaria.


Subject(s)
Chronic Urticaria , Dermatitis, Atopic , Hypersensitivity , Mesenchymal Stem Cells , Dermatitis, Atopic/therapy , Humans
19.
Annales de Dermatologie et de Vénéréologie - FMC ; 2022.
Article in English | ScienceDirect | ID: covidwho-1851105
20.
Dermatol Ther ; 35(7): e15573, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1832028

ABSTRACT

During the SARS-COV-2 pandemic, using face masks became mandatory in many countries. Although evidence suggests that masks can exacerbate several inflammatory skin diseases, few studies focus on their real impact on eczema localized to the face in atopic dermatitis (AD) patients. The aim of this study is to evaluate facial eczema prevalence during pandemic and its psychological impact in AD patients pre-assessed for systemic treatment and/or in therapy with dupilumab. This study includes 71 patients affected by moderate-severe AD, treated with dupilumab at SCDU of Dermatology in Novara, Italy. We calculated the number of subjects with facial involvement in pre- and post-pandemic periods and the related localization trend. We evaluated, in the two groups, clinical and psychological indicators recorded at each visit and the score modifications during the observational period. No statistically significant differences were observed in facial eczema prevalence, between pre- and post-pandemic periods (p = 0.7618) and in facial eczema remission among the two groups (p = 0.1903). In post-pandemic period, psychological scores were significantly lower (DLQI and HADS respectively with p < 0.0001 and p = 0.0025) and the reduction in EASI score during observational period was significantly greater (p = 0.0001). Our analysis revealed a potential protective effect of masks on face eczema, suggesting that they could enhance dupilumab efficacy. Face masks, covering sensitive areas, can positively contribute to mental distress in patients with facial eczema, and being associated with a lower allergic diseases incidence may sustain dupilumab in reducing AD severity.


Subject(s)
COVID-19 , Dermatitis, Atopic , Eczema , Facial Dermatoses , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/complications , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/epidemiology , Eczema/complications , Facial Dermatoses/complications , Humans , Pandemics/prevention & control , SARS-CoV-2 , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL